Related Experiment Video
Updated: Jun 15, 2026
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock: A Narrative Review in Light of Recent
Vincenzo Paragliola1,2, Marco Gamardella3, Luca Franchin2
1Division of Cardiology, School of Medicine and Surgery, Università degli Studi di Tor Vergata, 00133 Rome, Italy.
Insights
Cardiogenic shock (CS) management remains challenging. Percutaneous mechanical circulatory support (pMCS) devices show limited survival benefits, with higher complication rates, necessitating careful patient selection and further research.
Area of Science:
- Cardiology
- Critical Care Medicine
- Medical Devices
Background:
- Cardiogenic shock (CS) is a life-threatening condition with high mortality, often caused by acute myocardial infarction (AMI).
- The Society for Cardiovascular Angiography and Interventions (SCAI) classification aids in risk stratification and clinical decision-making for CS.
- Percutaneous mechanical circulatory support (pMCS) devices aim to improve hemodynamics in CS but have shown mixed results.
Purpose of the Study:
- To review the current evidence and clinical considerations for using percutaneous mechanical circulatory support (pMCS) devices in cardiogenic shock (CS).
- To evaluate the efficacy and safety of various pMCS devices, including intra-aortic balloon pump (IABP), Impella, and veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
Main Methods:
- Review of randomized trials, meta-analyses, and landmark studies (e.g., ECLS-SHOCK, DanGer) on pMCS in CS.
- Analysis of observational data on combined pMCS strategies (e.g., ECPELLA, ECMO + IABP).
- Consideration of hemodynamic guidance for device selection in specific failure types (e.g., Impella RP, Bi-Pella).
Main Results:
- Randomized trials have not consistently shown survival advantages for Impella over IABP, with higher complication rates reported.
- Conflicting results from landmark trials highlight the impact of patient severity and device timing.
- Combined strategies and specialized devices may address specific hemodynamic challenges but have considerable complication rates and limited robust data.
Conclusions:
- Current evidence suggests pMCS benefits in CS are restricted to carefully selected patient subgroups.
- Early diagnosis, prompt referral, and individualized treatment strategies are crucial for managing CS.
- Further robust randomized controlled trials are essential to define the optimal role and timing of pMCS in AMI-related CS.
Abstract:
Cardiogenic shock (CS) is a complex, life-threatening syndrome characterized by inadequate tissue perfusion due to impaired cardiac function. Acute myocardial infarction (AMI) and acute decompensated heart failure are the leading causes, with mortality remaining high despite advances in revascularization and supportive care. The Society for Cardiovascular Angiography and Interventions (SCAI) classification allows risk stratification and guides clinical decision making by capturing the spectrum of shock severity. Percutaneous mechanical circulatory support (pMCS) devices, such as the intra-aortic balloon pump (IABP) and Impella, aim to stabilize hemodynamics by augmenting cardiac output and unloading the left ventricle. However, randomized trials and meta-analyses have not demonstrated a consistent survival advantage of Impella over IABP, while reporting higher rates of bleeding and vascular complications. Landmark trials, including ECLS-SHOCK and DanGer, have provided conflicting results, likely reflecting differences in baseline severity and timing of device implantation. Veno-arterial extracorporeal membrane oxygenator (VA-ECMO) offers full cardiopulmonary support but increases left ventricular afterload, potentially worsening myocardial injury. Combined strategies such as ECPELLA (Impella + VA-ECMO) or ECMO + IABP may mitigate left ventricle (LV) overload and improve bridging to recovery or advanced therapies, although evidence remains largely observational and complication rates are considerable. In right-sided or biventricular failure, tailored options (e.g., Impella RP, Bi-Pella) guided by invasive hemodynamics may be required. Current evidence suggests that pMCS benefits are limited to carefully selected subgroups, underscoring the importance of early diagnosis, prompt referral, and individualized intervention. Robust randomized data are still needed to define the optimal role of pMCS in AMI-related CS.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...